SEC Form 4 · accession 0001209191-19-013710
Radius Health, Inc. · RDUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jesper Hoeiland
Officer — President and CEO · Director
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 6:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001428522
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.18 | Feb 22, 2019 | A | 128,000 | A | — | Feb 22, 2029 | Common Stock | 128,000 | 128,000 | D |
| Performance Stock UnitsF2 | — | Feb 22, 2019 | A | 71,000 | A | — | Feb 22, 2029 | Common Stock | 71,000 | 71,000 | D |
Explanation of responses
- F125% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates.
- F2Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. 50% of the restricted stock units shall vest upon the execution of a Board approved partnership for elacestrant within twelve months from the grant date of February 22, 2019, and, assuming such performance condition is achieved, the remaining restricted stock units shall vest on the third anniversary of the grant date of February 22, 2019, subject to continued service with RDUS through such dates.